Financial Gravity Asset Management, Inc. Myriad Genetics Inc Transaction History

Financial Gravity Asset Management, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$22.67 - $28.01 $13,964 - $17,254	-616 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$24.13 - $32.63 $14,864 - $20,100	616 New	616 $2.99 Million
Q1 2021 May 17, 2021	SELL	$19.92 - $31.6 $19 - $31	-1 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$12.16 - $19.77 $12 - $19	1 New	1 $0
Q2 2020 Aug 13, 2020	SELL	$10.69 - $16.49 $96 - $148	-9 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$9.78 - $29.53 $264 - $797	-27 Reduced 75.0%	9 $0
Q4 2019 Feb 28, 2020	SELL	$20.93 - $35.1 $7,534 - $12,636	-360 Reduced 90.91%	36 $27,000
Q3 2019 Oct 15, 2019	SELL	$22.08 - $47.08 $11,238 - $23,963	-509 Reduced 56.24%	396 $11,000
Q2 2019 Jul 26, 2019	SELL	$22.67 - $35.0 $17,818 - $27,510	-786 Reduced 46.48%	905 $25,000
Q1 2019 Apr 19, 2019	BUY	$26.93 - $34.7 $41,849 - $53,923	1,554 Added 1134.31%	1,691 $56,000
Q3 2018 Oct 31, 2018	SELL	$37.57 - $50.34 $39,974 - $53,561	-1,064 Reduced 88.59%	137 $6,000
Q2 2018 Aug 14, 2018	BUY	$27.75 - $40.17 $28,554 - $41,334	1,029 Added 598.26%	1,201 $51,000
Q1 2018 May 23, 2018	BUY	$28.83 - $41.01 $4,958 - $7,053	172 New	172 $5,000

253

90.5M

100K

34K

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.09B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.